Related Experiment Videos
Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection
Benjamin M Segal1, Deborah D Glass, Ethan M Shevach
1Department of Neurology, The Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. Benjamin_segal@urmc.rochester.edu
Journal of Immunology (Baltimore, Md. : 1950)
|December 26, 2001
Summary
Regulatory T cells producing interleukin-10 (IL-10) typically suppress immunity. However, this study reveals that IL-10-producing CD4+ T cells promote glioma tumor rejection, challenging prior assumptions about IL-10
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Interleukin-10 (IL-10) is known for its potent immunosuppressive functions.
- CD4+ Tr1 cells, which produce IL-10, are generally recognized as regulators of T-helper 1 (Th1) immunity.
- The role of IL-10 in cancer immunity is complex and context-dependent.
Purpose of the Study:
- To investigate the role of CD4+ T cells and IL-10 in tumor rejection within a glioma mouse model.
- To determine the cytokine profile of glioma-specific CD4+ T cells following vaccination.
- To clarify the function of IL-10-producing CD4+ T cells in antitumor immunity.
Main Methods:
- Utilized a subcutaneous (s.c.) glioma cell growth model in mice.
- Administered vaccination with irradiated glioma cells.
- Analyzed the role of CD4+ and CD8+ T cells in tumor rejection.
- Assessed tumor rejection in IL-10 knockout (IL-10(-/-)) mice.
- Measured cytokine production (IL-10, IL-4, IFN-gamma) by glioma-specific CD4+ T cells.
Main Results:
- CD4+ T cells, but not CD8+ T cells, were critical for tumor rejection after vaccination.
- Glioma-specific CD4+ T cells predominantly produced IL-10, with minimal IL-4 or IFN-gamma.
- Tumor rejection was significantly impaired in IL-10(-/-) mice, indicating a pro-rejection role for IL-10.
- This suggests IL-10-producing CD4+ T cells can exert antitumor functions.
Conclusions:
- IL-10-producing CD4+ T cells can mediate antitumor immunity, contrary to their typical immunosuppressive role.
- IL-10 may exhibit context-dependent pro-inflammatory or pro-tumor rejection effects in certain disease states.
- These findings have implications for cancer immunotherapy strategies involving T cell modulation.